Roche has launched a new genomic profiling kit to help laboratories strengthen their in-house cancer research.
The new AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit is a research use only sequencing assay developed to offer an end-to-end workflow from DNA extraction and library preparation to generation of variant results.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is developed by Roche, in collaboration with its unit Foundation Medicine, to further bolster its CGP portfolio.
Researchers can use the AVENIO Tumor Tissue CGP Kit with Foundation Medicine’s comprehensive genomic profiling for oncology research in their own laboratories. This eliminates the need to send tissue samples to centralised laboratories.
The kit will also provide information on complex genomic signatures such as tumour mutational burden (TMB), microsatellite instability (MSI) and loss of heterozygosity (LOH).
According to Roche, a future version of the kit may provide clinicians with additional resources for the diagnosis and treatment of cancer.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRoche Diagnostics CEO Thomas Schinecker said: “To treat cancer effectively, we must understand what drives it at a molecular level. CGP helps inform decisions about available treatment options, including targeted therapies, immunotherapies, tumour-agnostic treatments and clinical trial participation, based on the unique genomic profile of a patient’s tumour.
“We are bringing powerful insights from CGP to enable smarter, more efficient research and development. Our new kit provides the information researchers need and will ultimately provide insights physicians can use to develop personalised treatment strategies for individual patients.”
The AVENIO Tumor Tissue CGP Kit leverages a gene panel based on the FoundationOne platform designed to match the FoundationOne CDx panel content to assess 324 cancer-related genes across four main classes of genomic alterations and signatures.
Each of the kits can run 24 samples.
Earlier this month, the US Food and Drug Administration (FDA) approved the Roche VENTANA PD-L1 (SP263) Assay as a companion test for lung cancer.
